beeldscherm schreef op 10 november 2017 09:40:
dit is wel leuk nieuws v sept 2017,
EMA Finds No Difference in Inhibitor Risk Between Factor VIII Classes.
The European Medicines Agency (EMA) on Friday said it could find "no clear and consistent" evidence of a difference in the risk of inhibitor development between recombinant and plasma-derived factor VIII medicines
www.raps.org/Regulatory-Focus/News/20...- -
waar ik dit toch een belangrijker passage vind,
The study, Survey of Inhibitors in Plasma-Product Exposed Toddlers (SIPPET), looked at some 250 male children under 6 years of age at the time of screening who were randomly assigned plasma-derived (n=125) or recombinant (n=126) factor VIII products. According to the results of the study, 29 patients in the plasma-derived arm developed inhibitors and 47 in the recombinant arm developed inhibitors.